{"id":48467,"date":"2022-06-09T05:21:17","date_gmt":"2022-06-09T05:21:17","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=93078"},"modified":"2022-06-09T05:21:17","modified_gmt":"2022-06-09T05:21:17","slug":"international-nash-day-highlights-a-common-but-unfamiliar-liver-disease","status":"publish","type":"post","link":"https:\/\/southafricatribune.com\/international-nash-day-highlights-a-common-but-unfamiliar-liver-disease\/","title":{"rendered":"International NASH Day Highlights a Common \u2013 But Unfamiliar \u2013 Liver Disease"},"content":{"rendered":"
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) — Global Liver Institute (GLI) <\/a>calls attention to NASH by leading the 5th annual International NASH Day<\/a> on June 9. The number of people with this advanced liver disease is expected to double<\/a> by 2030, but #NASHday aims to prevent this growth. Join the movement to #StopNASHNow by listening in<\/a> as 24 expert panelists from around the globe share the latest updates about the disease or adding to the conversation on social media (#NASHday). The movement permeates the globe through many locally-organized events to educate about, screen for, and prevent NASH.<\/p>\n NASH (nonalcoholic steatohepatitis) is a serious, progressive condition in which too much fat accumulates on the liver, leading to its inflammation and injury. It is the severe form of NAFLD (nonalcoholic fatty liver disease). Modern lifestyle and dietary patterns have contributed to increased prevalence<\/a> of NASH and NAFLD around the world, and it is becoming the most common cause of liver disease. Given its widespread impact and the possibility of prevention in most cases of this disease, NASH emerges as a global health priority.<\/p>\n \u201cWith over a hundred million people worldwide already who have NASH and several times more in the earlier stages, people have reason to know about this progressive condition and what they can do today to combat it,\u201d shared Donna R. Cryer<\/a>, president and CEO of GLI. \u201cCollective action is imperative to be certain that individuals in each community, no matter their background or environment, are informed and equipped to prevent fatty liver disease. The momentum that we build together today must advance and sustain the global fight against NASH.\u201d<\/p>\n If you didn\u2019t know, then now you know! Even though NASH is common, it remains relatively unknown, leaving much work to be done to increase public awareness. This year, GLI and its partners join with the theme to #StopNASHNow: Even as therapies for NASH are being developed, there are many steps that people and their doctors can take today<\/em> to prevent, reverse, or slow the progression of fatty liver disease. For the 25% of adults already affected worldwide, it is due time for this life-changing knowledge.<\/p>\n \u201cInternational NASH Day demonstrates the potential that is realized as all stakeholders in NASH come together worldwide,\u201d said Jeff McIntyre<\/a>, NASH Programs Director at GLI. \u201cFrom in-person screenings in at-risk communities to educational materials in 16 languages to challenging conversations with researchers, providers, and patients \u2013 today the world joins to create meaningful solutions for patients at every stage of NAFLD and NASH.\u201d<\/p>\n International NASH Day has garnered the endorsement of prominent organizations from around the globe: American Association for the Study of Liver Diseases (AASLD); Association of Black Gastroenterologists and Hepatologists (ABGH); Asociaci\u00f3n Latinoamericana para el Estudio del H\u00edgado (ALEH); Associazione Italiana Studio del Fegato (AISF); Asociaci\u00f3n Mexicana de Hepatolog\u00eda (AMH); Asian Pacific Association for the Study of the Liver (APASL); Canadian Association for the Study of the Liver (CASL); Conference on Liver Disease in Africa (COLDA); European African Treatment Advocates Network (EATAN); European Fatty Liver Conference (EFLC); European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN); EU Patient-Centric Clinical Trial Platforms (EU-PEARL); Fondazione Epatocentro Ticino; Hepatology Society, Dhaka, Bangladesh; Hepatology Society of the Philippines (HSP); Indian National Association for the Study of the Liver (INASL); North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN); Sociedad Argentina de Hepatologia (SAHE);Turkish Association for the Study of the Liver (TASL); United European Gastroenterology (UEG); World Gastroenterology Organisation (WGO); and World Patients Alliance (WPA).<\/p>\n Get Involved<\/strong><\/p>\n To view the expert panels throughout the day today, visit https:\/\/hopin.com\/events\/5th- For additional information on International NASH Day, visit www.international-nash-day.com<\/a> Support the NASH Day social media campaign using hashtags #NASHday #StopNASHNow. Please direct any additional questions to NASHDay@globalliver.org<\/a>.<\/p>\n International NASH Day and its logo are registered trademarks of Global Liver Institute.<\/p>\n About Global Liver Institute<\/strong><\/p>\n Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Twitter<\/a>, Facebook<\/a>, Instagram<\/a>, LinkedIn<\/a>, and YouTube<\/a>. GLI is the global host of International NASH Day.<\/p>\n Global Liver Institute Convenes Communities Around the Globe Today to Reverse the Growing Trend of Fatty Liver Disease Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) \u2014 Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this advanced liver disease is [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[175],"tags":[],"yoast_head":"\n\n
Global Liver Institute\r\nnashday@globalliver.org<\/a>\r\n<\/pre>\n<\/div>\n","protected":false},"excerpt":{"rendered":"